The 13 references in paper D. Naskhletashvili R., V. Gorbunova A., M. Bychkov B., A. Bekyashev Kh., V. Karakhan B., V. Aleshin A., D. Belov M., E. Moskvina A., Д. Насхлеташвили Р., В. Горбунова А., М. Бычков Б., А. Бекяшев Х., В. Карахан Б., В. Алешин А., Д. Белов М., Е. Москвина А. (2015) “БЕВАЦИЗУМАБ В СОЧЕТАНИИ С ИРИНОТЕКАНОМ В ЛЕЧЕНИИ РЕЦИДИВОВ ГЛИОБЛАСТОМ // BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS” / spz:neicon:ogsh:y:2012:i:3:p:56-58

1
Cloughesy T.F., Prados M.D., Mikkelsen T. et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) (abstract). Clin Oncol 2008;26:2010b.
(check this in PDF content)
2
Fisher J.L., Schwartzbaum J.A., Wrensch M. et al. Epidemiology of brain tumors. Neurol Clin 2007;25:867–90.
(check this in PDF content)
3
Kreisl T.N., Kim L., Moore K. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab and irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740–5.
(check this in PDF content)
4
Nghiemphu P.L., Liu W., Lee Y. et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217–22.
(check this in PDF content)
5
Norden A.D., Young G.S., Setayesh K. et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779–87. 5757
(check this in PDF content)
6
Pope W.B., Lai A., Nghiemphu P. et al. Cloughesy T.E. MRI in patients with highgrade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258–60.
(check this in PDF content)
7
Schmidt N.O., Westphal M., Hagel C. et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factoring human gliomas and their relation to angiogenesis. Int J Cancer 1999;84:10–8.
(check this in PDF content)
8
Stark-Vancs V. Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma (abstract). Neurooncol 2005;7:369.
(check this in PDF content)
9
Stupp R., Hegi M.E., Gilbert M.R. et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25:4127–36.
(check this in PDF content)
10
Vredenburgh J.J., Desjardins A., Herndon J.E. 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722–9.
(check this in PDF content)
11
Wagner S.A., Desjardins A., Reardon D.A. et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas (abstract). J Clin Oncol 2008;26:2021.
(check this in PDF content)
12
Vredenburgh J.J., Desjardins A., Herndon J.E. 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253–9.
(check this in PDF content)
13
Yung W.K., Albright R.E., Olson J. et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588–93. Опухо
(check this in PDF content)